Table 1.
Key characteristics of the study cohort
| Variable | All (n = 1403) |
Developed diabetes (n = 523) |
Did not develop diabetes (n = 880) |
|---|---|---|---|
| Male | 779 (55.5) | 293 (56.0) | 486 (55.2) |
| Age at seroconversion, initial visit (years) | |||
| Mean ± SD | 5.6 ± 4.2 | 3.6 ± 2.9 | 6.7 ± 4.3 |
| Range | 0.3–23.3 | 0.3–16.8 | 0.3–23.3 |
| Age at seroconversion, confirmatory visit (years) | |||
| Mean ± SD | 6.1 ± 4.3 | 4.1 ± 3.1 | 7.2 ± 4.5 |
| Range | 0.5–23.9 | 0.5–18.7 | 0.5–23.9 |
| Data source | |||
| BABYDIAB | 156 (11.1) | 39 (7.5) | 117 (13.3) |
| DAISY | 178 (12.7) | 64 (12.2) | 114 (13.0) |
| DEW-IT | 173 (12.3) | 42 (8.0) | 131 (14.9) |
| DIPIS | 69 (4.9) | 17 (3.3) | 52 (5.9) |
| DIPP | 827 (58.9) | 361 (69.0) | 466 (53.0) |
| HLA risk group | |||
| A | 333 (23.7) | 183 (35.0) | 150 (17.0) |
| B | 666 (47.5) | 248 (47.4) | 418 (47.5) |
| C | 182 (13.0) | 46 (8.8) | 136 (15.5) |
| D | 219 (15.6) | 46 (8.8) | 173 (19.7) |
| Missing | 3 (0.2) | 0 (0.0) | 3 (0.3) |
| Autoantibody-positive at seroconversion (initial visit) | |||
| IAA | 704 (50.2) | 326 (62.3) | 378 (43.0) |
| GADA | 707 (50.4) | 290 (55.4) | 417 (47.4) |
| IA-2A | 276 (19.7) | 166 (31.7) | 110 (12.5) |
| Autoantibody level at seroconversion (initial visit) (mULN) | |||
| IAA | 3.1 ± 8.2 | 4.5 ± 11.0 | 2.3 ± 6.7 |
| GADA | 5.7 ± 27.9 | 7.6 ± 34.2 | 4.6 ± 24.3 |
| IA-2A | 13.6 ± 59.8 | 25.2 ± 72.9 | 6.7 ± 52.0 |
| Autoantibody-positive at seroconversion (confirmatory visit) | |||
| IAA | 787 (56.1) | 364 (69.6) | 423 (48.1) |
| GADA | 865 (61.7) | 381 (72.8) | 484 (55.0) |
| IA-2A | 416 (29.7) | 278 (53.2) | 138 (15.7) |
| Autoantibody level at seroconversion (confirmatory visit) (mULN) | |||
| IAA | 4.4 ± 12.6 | 7.4 ± 16.4 | 2.7 ± 9.2 |
| GADA | 9.5 ± 64.6 | 13.9 ± 75.7 | 6.9 ± 56.9 |
| IA-2A | 24.5 ± 75.7 | 50.4 ± 94.0 | 9.0 ± 57.0 |
Data are presented as n (%), means ± SD, or range
Percentages may not total to 100 because of rounding. Autoantibody-positive percentages may not total to 100 due to multiple positivity